Adesão terapêutica e gerenciamento de um paciente com esquizofrenia durante Acompanhamento Farmacoterapêutico ambulatorial: relato de caso

Introduction. Social stigmas and the constraining effects of chronic antipsychotic therapy are factors influencing low therapeutic adherence. This study presents a case with a favorable prognosis after seven months of pharmaceutical monitoring at a specialized public outpatient mental health center. Case report. The subject is a 29-year-old man diagnosed with schizophrenia (ICD F20.0), who recently experienced a psychotic episode with both positive and negative symptoms. The patient exhibited non-adherence to prescribed medications, including haloperidol, risperidone, nortriptyline, and diazepam, with no reported psychological therapy. Baseline objective data revealed a body mass index below reference values, and borderline blood pressure and capillary blood glucose levels. During consultations, pharmacotherapy-related problems (PRF) were identified, such as low therapeutic adherence, drug interactions, inappropriate administration frequency, inadequate treatment duration, and significant adverse reactions. Pharmaceutical interventions included health education, therapeutic adjustments in collaboration with the prescriber, and referrals to other services. Ultimately, psychometric scales confirmed medication adherence and improvement in depressive and anxious symptoms. Discussion. Pharmacotherapeutic monitoring proved significantly relevant, facilitating not only the detection but also the resolution of PRF while fostering health improvement. Conclusion. In this context, it enabled the management of therapeutic efficacy and safety, thereby increasing the patient's prospects for greater social integration.